Takeda defeats sham litigation claims

Takeda Pharmaceuticals had a reasonable basis for alleging a generic drugmaker infringed upon its patented heartburn medication, a New Jersey federal court has said in finding the pharmaceutical company immune from allegations it illegally maintained a monopoly over Prevacid SoluTab.


Get unlimited access to all Global Competition Review content